Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024
With 60% Ownership, Caribou Biosciences, Inc. (NASDAQ:CRBU) Boasts of Strong Institutional Backing
Vir Biotechnology Names Jason O'Byrne Finance Chief
Truist Financial Initiates Caribou Biosciences(CRBU.US) With Buy Rating
Truist Financial analyst Jailendra Singh initiates coverage on $Caribou Biosciences(CRBU.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 35.0% and a total
Caribou Biosciences Announces CFO Resignation and Succession Plan
Express News | Caribou Biosciences- Plans to Appoint Ryan Fischesser to Assume Role of Principal Accounting Officer, Effective as Close of Business on Sept 27
Express News | Caribou Biosciences Inc - on Sept 1 Jason O'byrne, CFO, Informed of Intent to Resign From Position
Caribou Biosciences (CRBU) Receives a Buy From H.C. Wainwright
Express News | Caribou Biosciences Inc: CB-010 Gallop Phase 1 Trial in Patients With Ln and Erl Is on Track to Initiate by Ye 2024
Express News | Caribou Biosciences Announces the FDA Has Granted Fast Track Designations to CB-010 in Refractory Sle and to CB-012 in Relapsed or Refractory Aml
Caribou Biosciences Announces the FDA Has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML
Caribou Biosciences to Participate in Upcoming Investor Conferences
Caribou Coffee Brings a Taste of the Apple Orchard to Its New Fall Menu
H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $9
H.C. Wainwright analyst Robert Burns maintains $Caribou Biosciences(CRBU.US)$ with a buy rating, and maintains the target price at $9.According to TipRanks data, the analyst has a success rate of 24.4
HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $9 Price Target
Caribou Biosciences: A Strong Buy on Solid Financials and Promising Trials
Express News | Caribou Biosciences Appoints Tina Albertson, Md, Phd, as Chief Medical Officer
Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer
Bank of America Securities Keeps Their Buy Rating on Caribou Biosciences (CRBU)
Express News | Caribou Biosciences Inc : BofA Global Research Cuts Price Objective to $15 From $17